If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
60
results.
Updated on
24/12/2025 [07:36:00]
Absstract of: US2025380912A1
One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off.
Absstract of: WO2025258837A1
The present invention relates to an optical sensor and a wearable device comprising the same for non-invasively determining a concentration of blood components, for example, blood glucose and glycated hemoglobin levels. The optical sensor comprises an emitter configured to emit short-wave infrared (SWIR) radiation, an insulator with a channel transparent to the SWIR radiation, the emitter being disposed on top of the insulator and configured to emit the radiation into a biological tissue through the transparent channel, an optical concentrator made from a material with a refractive index of 1.7 or more, and a photodetector disposed in an upper part of the optical concentrator. The invention provides the possibility of non-invasive, instant or continuously monitoring of blood glucose and glycated hemoglobin levels. 2 indep. claims and 13 dep. claims, 15 figs., 2 tables.
Absstract of: WO2025259242A1
The invention relates to a manually controlled manual insulin pump configuration suitable for use by diabetic individuals who have to inject with an insulin pen before each meal or high blood sugar correction dose.
Absstract of: CN120787146A
Intravascular artificial pancreatic devices and methods of making the same are disclosed herein.
Absstract of: EP4663120A1
One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off.
Absstract of: EP4664482A2
The present disclosure relates to a method for transmitting or receiving biometric information in a continuous glucose monitoring system and, more specifically, to a method for transmitting or receiving biometric information, in which: when a sensor transmitter generates a transmission packet, the transmission packet is generated to include a generation identifier for identifying the transmission packet or biometric information according to a generation order of the transmission packet or the biometric information, and therefore the biometric information may be transmitted or received without a loss thereof via the generation identifier; and a transmission packet or biometric information, which a communication terminal has failed to receive, is correctly determined on the basis of a packet generation identifier or a total number of transmission packets, so that only biometric information or a transmission packet, which has failed to be received between the sensor transmitter and the communication terminal, may be transmitted or received in a distinguished manner.
Absstract of: WO2025253234A1
A system and method for non-invasive blood glucose level determination and proactive management are disclosed. A sensing device comprises a capacitance-to-digital converter (CDC) sensor, featuring an active shield electrode and single-ended mode operation, to measure capacitance variations indicative of net body charge modulation by systemic physiological activity correlated with blood glucose. The device also includes at least one skin conductance sensor. A processor determines blood glucose levels from combined CDC and skin conductance data, optionally using machine learning. Further, a proactive artificial intelligence (AI) system, employing supervised and reinforcement learning models, analyzes real-time and historical data to predict blood glucose trajectories and the likelihood of future dysregulation. Crucially, the AI dynamically generates a personalized schedule of recommended actions (e.g., relating to diet, exercise, or medication timing) for managing the subject's blood glucose, providing alerts and the action plan to enhance diabetes self-management.
Absstract of: WO2025254973A1
A computational continuous glucose monitoring system is disclosed which integrates a biocompatible phosphorescence-based insertable sensor and a custom-designed phosphorescence imager (PI). This PI captures phosphorescence lifetime images of an insertable sensor through the skin where the lifetime of the emitted phosphorescence signal is modulated by the local concentration of glucose. The lifetime images acquired through the skin are processed by neural network-based models for misalignment-tolerant inference of glucose levels, accurately revealing normal, low (hypoglycemia) and high (hyperglycemia) concentration ranges. Using a 1-mm thick skin phantom mimicking the optical properties of human skin, in vitro testing of the PI using glucose-spiked samples yielded 88.8% inference accuracy, also showing resilience to random and unknown misalignments within a lateral distance of ~4.7 mm. Lateral misalignments beyond 5 mm prompted user intervention for re-alignment.
Absstract of: US2025375574A1
A method for improving blood glucose control of a hybrid controller meal and exercise announcement by substituting patient-initiated meal boluses of said hybrid controller by an automatic insulin correction signal without retuning of said hybrid controller, and by incorporating rescue carbohydrates suggestion for hypoglycemia mitigation, comprising the steps of measuring a plasma glucose (G(t)) signal by means of a continuous glucose monitor (CGM), calculating a glucose level (Ĝ(t)) by using a glucose-insulin model; computing a disturbance term d(t), generating a virtual signal uIMC(t), for mitigating the effect of d(t) on the output, by means of an IMC filter Q(s) and converting the virtual signal uIMC(t) into three feed forward actions: insulin infusion, rescue carbohydrate suggestion, and insulin-on-board reduction.
Absstract of: US2025377296A1
A process and sensor system with particular control of polarization of the interrogating light beams useful for determining a concentration of a targeted molecule M (such as glucose) within a given time period in a liquid sampling matrix through use of a Direct Infrared Laser Absorption Spectroscopy Technique.
Absstract of: WO2025255026A1
A device for delivering medication to a user, the device configured to be mounted to the user, the device comprising: (a) a baseplate and a housing configured to engage the baseplate to form an interior therein; (b) a platform mounted to the baseplate within the interior, the platform configured to support a micropump having an inlet port for communicating with a reservoir and an outlet port for communicating with a cannula for delivering the medication to the use.
Absstract of: US2025375573A1
A simplified insulin pump allows diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.
Absstract of: WO2024160808A1
The present disclosure relates to highly integrated sensor devices such as implantable devices, continuous monitoring devices and portable smart devices for determining a physiological parameter in a bodily fluid and/or tissue of a subject. Further, the present disclosure relates to methods for determining a physiological parameter in a bodily fluid and/or tissue of a subject.
Absstract of: US2025366749A1
Disclosed herein are devices, systems, and methods for a continuous analyte sensor, such as a continuous glucose sensor. In certain embodiments disclosed herein, various in vivo properties of the sensor's surroundings can be measured. In some embodiments, the measured properties can be used to identify a physiological response or condition in the body. This information can then be used by a patient, doctor, or system to respond appropriately to the identified condition.
Absstract of: US2025366743A1
Methods, systems, and devices for regulating blood glucose such as implantable encapsulated devices optionally with insulin and/or glucagon secreting cells in combination with glucose sensors and insulin infusion systems. For example, encapsulation devices may be connected to an insulin infusion pump for distribution of insulin. The insulin infusion pump may feature an insulin pouch fluidly connected to an insulin pump (or a syringe) and a glucose sensor separate from the encapsulation device. The system may feature an additional implantable device comprising insulin and glucagon secreting cells.
Absstract of: WO2025249486A1
Provided are a program, a system, an information processing device, a server, and a method capable of executing a game in which a game effect occurs on the basis of continuously measured biological information. There is provided a program to be executed by a computer including a processor and a memory, the program causing the processor to execute a step of acquiring continuous blood glucose level data of a user associated with time information including an acquisition time prior to an acquisition time point, and a step of generating a predetermined game effect on the basis of the continuous blood glucose level data within a predetermined time period.
Absstract of: WO2025245624A1
It is provided an insulin formulation comprising insulin and antimicrobial excipients for use in insulin pumps, connected to subcutaneous tissue via a catheter, a method also known as continuous subcutaneous insulin infusion, wherein the antimicrobial excipient inhibits growth of bacteria in insulin formulations and biofilm bacterial population formation on the internal surfaces of a catheter, allowing extending the time of use of the catheter.
Absstract of: AU2025267469A1
22222883_1 (GHMatters) P120626.AU.1 In some aspects, a system is provided for gathering and processing sensor data to identify a risk of impacting or causing a venous leg ulcer, wherein the system includes computer- readable memory and one or more processors and is configured to: obtain sensor feature data including a set of feature data representing output of a user sensor configured to be worn on a limb of a user; determine an activity classification using the set of feature data and an activity classification model, wherein the activity classification model includes a decision tree configured to assign the set of feature data to one of a plurality of different activity classifications wherein the different activity classifications comprises: i a first activity classification representing motion of the limb; ii a second activity classification representing no motion of the limb with static weight such as standing; and iii a third activity classification representing that the user is lying down; wherein the system is further configured to generate display data representing the activity classification; and transmit the display data to a computing device configured to present the display data. ov o v
Absstract of: US2025367370A1
A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Absstract of: US2025367371A1
A hybrid bioelectronic implantable device containing engineered cells for delivery of therapeutic agents to a subject to treat a medical condition of the subject. The device comprises an implantable device implantable inside the subject's body, wherein the implantable device comprises at least one cell housing containing the engineered cells; and an optical stimulating system within the at least one cell housing, wherein the optical stimulating system is configured to control production of at least one type of therapeutic agents by the engineered cells; wherein the medical condition of the subject comprises one of a sleep disorder, a circadian rhythm disorder, neuro disorders, infertilities, diabetes, obesity, eating disorders, cancers, bone marrow disorders, autoimmune disorders, addictive disorders.
Absstract of: US2025367380A1
Techniques for automatic device configuration are disclosed herein. In some embodiments, the techniques involve receiving patient data by one or more processors of a cloud-based server device. The techniques further involve obtaining, by the cloud-based server device, and based on the patient data, a value of a total daily dose of insulin for the specific patient. The techniques further involve automatically selecting, by the cloud-based server device, before the medical device has been set up to deliver insulin to the specific patient, a therapy configuration for the medical device. The techniques further involve determining, by the cloud-based server device, a set of therapy settings for the selected therapy configuration for the specific patient based upon the value of the total daily dose. The techniques further involve automatically configuring, via a non-medical device, the medical device with the set of therapy settings in a startup mode.
Absstract of: US2025367366A1
An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.
Absstract of: US2025366741A1
One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.
Absstract of: US2025366742A1
One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved.
Nº publicación: WO2025245938A1 04/12/2025
Applicant:
MEDTRUM TECH INC [CN]
\u4E0A\u6D77\u79FB\u5B87\u79D1\u6280\u6709\u9650\u516C\u53F8
Absstract of: WO2025245938A1
A personalized closed-loop infusion system and method. Relevant information of patients is uploaded to a cloud server (104), and is grouped on the basis of identifiable features of the patients; the relevant information of different patients, such as blood glucose data records and insulin infusion data records, is compared in a same group; and when the relevant information of the patients is the same or similar, insulin algorithm parameters of patients with well-controlled blood glucose can be used for modifying an insulin algorithm of patients with poorly-controlled blood glucose, and a closed-loop artificial pancreas system can quickly obtain personalized insulin algorithms suitable for the patients without the need of long-period learning of physiological characteristics and lifestyle habits of the patients, thereby benefiting diabetes treatment of the patients.
BOPI
Electronic site
